Endonovo Therapeutics, Inc. filed its 10-K on Apr 14, 2022 for the period ending Dec 31, 2021. In this report its auditor, Rose, Snyder & Jacobs, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0015 USD | -40.00% | -40.00% | -82.76% |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
1st Jan change | Capi. | |
---|---|---|
-82.76% | 524K | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ENDV Stock
- News Endonovo Therapeutics, Inc.
- Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt